Trial Profile
A retrospective study to evaluate the Pirfenidone dose adjustment by body weight/surface area in patients with Interstitial Pneumonia and idiopathic pulmonary fibrosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Sep 2017
Price :
$35
*
At a glance
- Drugs Pirfenidone (Primary)
- Indications Idiopathic pulmonary fibrosis; Interstitial lung diseases
- Focus Adverse reactions; Therapeutic Use
- 29 Aug 2017 Results published in the Respirology.
- 13 Jul 2017 New trial record
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society